<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25268838</article-id><article-id pub-id-type="pmc">4210906</article-id><article-id pub-id-type="doi">10.3390/nu6104043</article-id><article-id pub-id-type="publisher-id">nutrients-06-04043</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effects of Perioperative Supplementation with Omega-3 Fatty Acids on Leukotriene B<sub>4</sub> and Leukotriene B<sub>5</sub> Production by Stimulated Neutrophils in Patients with Colorectal Cancer: A Randomized, Placebo-Controlled Intervention Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sorensen</surname><given-names>Lone S.</given-names></name><xref ref-type="aff" rid="af1-nutrients-06-04043">1</xref><xref rid="c1-nutrients-06-04043" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Thorlacius-Ussing</surname><given-names>Ole</given-names></name><xref ref-type="aff" rid="af1-nutrients-06-04043">1</xref><xref ref-type="aff" rid="af2-nutrients-06-04043">2</xref></contrib><contrib contrib-type="author"><name><surname>Rasmussen</surname><given-names>Henrik H.</given-names></name><xref ref-type="aff" rid="af3-nutrients-06-04043">3</xref></contrib><contrib contrib-type="author"><name><surname>Lundbye-Christensen</surname><given-names>S&#x000f8;ren</given-names></name><xref ref-type="aff" rid="af4-nutrients-06-04043">4</xref></contrib><contrib contrib-type="author"><name><surname>Calder</surname><given-names>Philip. C.</given-names></name><xref ref-type="aff" rid="af5-nutrients-06-04043">5</xref></contrib><contrib contrib-type="author"><name><surname>Lindorff-Larsen</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="af6-nutrients-06-04043">6</xref></contrib><contrib contrib-type="author"><name><surname>Schmidt</surname><given-names>Erik B.</given-names></name><xref ref-type="aff" rid="af4-nutrients-06-04043">4</xref></contrib></contrib-group><aff id="af1-nutrients-06-04043"><label>1</label>Department of Surgical Gastroenterology, Aalborg University Hospital, 9000 Aalborg, Denmark; E-Mail: <email>otu@rn.dk</email></aff><aff id="af2-nutrients-06-04043"><label>2</label>Institute of Clinical Medicine, Aarhus University Hospital, Aarhus 8000, Denmark</aff><aff id="af3-nutrients-06-04043"><label>3</label>Center for Nutrition and Bowel Disease, Aalborg University Hospital, 9000 Aalborg, Denmark; E-Mail: <email>hhr@rn.dk</email></aff><aff id="af4-nutrients-06-04043"><label>4</label>Department of Cardiology, Center for Cardiovascular Research, Aalborg University Hospital, 9000 Aalborg, Denmark; E-Mails: <email>solc@rn.dk</email> (S.L.); <email>ebs@rn.dk</email> (E.B.S.)</aff><aff id="af5-nutrients-06-04043"><label>5</label>National Institute for Health Research Southampton Biomedical Research Center, University Hospital Southampton NHS Foundation Trust and University of Southampton, Southampton SO16 6YD, UK; E-Mail: <email>p.c.calder@soton.ac.uk</email></aff><aff id="af6-nutrients-06-04043"><label>6</label>NordSim, Center for Simulation, Skills Training, Science and Innovation, Aalborg University Hospital, 9000 Aalborg, Denmark; E-Mail: <email>kgll@rn.dk</email></aff><author-notes><corresp id="c1-nutrients-06-04043"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>lss@rn.dk</email>; Tel.: +45-9766-1188; Fax: +45-9932-2560.</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2014</year></pub-date><volume>6</volume><issue>10</issue><fpage>4043</fpage><lpage>4057</lpage><history><date date-type="received"><day>30</day><month>7</month><year>2014</year></date><date date-type="rev-recd"><day>18</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2014</copyright-year><license><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Omega-3 fatty acids (<italic>n</italic>-3 FA) may have beneficial clinical and immune-modulating effects in surgical patients. In a randomized, double-blind, prospective, placebo-controlled trial, 148 patients referred for elective colorectal cancer surgery received an <italic>n</italic>-3 FA-enriched oral nutritional supplement (ONS) providing 2.0 g of eicosapentaenoic acid (EPA) and 1.0 g of docosahexaenoic acid (DHA) per day or a standard ONS for seven days before surgery. On the day of operation, there was a significant increase in the production of leukotriene B<sub>5</sub> (LTB<sub>5</sub>) (<italic>p</italic> &#x0003c; 0.01) and 5-hydroxyeicosapentaenoic acid (5-HEPE) (<italic>p</italic> &#x0003c; 0.01), a significant decrease in the production of leukotriene B<sub>4</sub> (LTB<sub>4</sub>) (<italic>p</italic> &#x0003c; 0.01) and a trend for a decrease in the production of 5-hydroxyeicosatetraenoic acid (5-HETE) (<italic>p</italic> &#x0003c; 0.1) from stimulated neutrophils in the active group compared with controls. There was no association between LTB<sub>4</sub> values and postoperative complications. In conclusion, oral <italic>n</italic>-3 FA exerts anti-inflammatory effects in surgical patients, without reducing the risk of postoperative complications.</p></abstract><kwd-group><kwd>colorectal cancer</kwd><kwd>omega-3 fatty acids</kwd><kwd>immunomodulation</kwd><kwd>fish oil</kwd><kwd>leukotrienes</kwd></kwd-group></article-meta></front><body><sec><title>1. Introduction</title><p>Patients undergoing surgery are at risk of developing complications in the postoperative period [<xref rid="B1-nutrients-06-04043" ref-type="bibr">1</xref>,<xref rid="B2-nutrients-06-04043" ref-type="bibr">2</xref>,<xref rid="B3-nutrients-06-04043" ref-type="bibr">3</xref>]. This is believed to be partly caused by changes in the immune response following surgery [<xref rid="B4-nutrients-06-04043" ref-type="bibr">4</xref>]. Thus, initially, a hyper-inflammatory response followed by a phase of relative immune incompetence occurs in relation to major surgery [<xref rid="B5-nutrients-06-04043" ref-type="bibr">5</xref>].</p><p>The pathophysiological changes are complex, but may be driven by excessive production of various lipid mediators, including the very potent pro-inflammatory leukotriene B<sub>4</sub> (LTB<sub>4</sub>) produced from the omega-6 fatty acid (<italic>n</italic>-6 FA) arachidonic acid (AA) present in cell membranes. </p><p>Among factors known to influence the clinical course of patients after surgery are nutritional status and specific biologically active nutrients [<xref rid="B2-nutrients-06-04043" ref-type="bibr">2</xref>,<xref rid="B6-nutrients-06-04043" ref-type="bibr">6</xref>,<xref rid="B7-nutrients-06-04043" ref-type="bibr">7</xref>,<xref rid="B8-nutrients-06-04043" ref-type="bibr">8</xref>,<xref rid="B9-nutrients-06-04043" ref-type="bibr">9</xref>,<xref rid="B10-nutrients-06-04043" ref-type="bibr">10</xref>] that might include the marine omega-3 fatty acids (<italic>n</italic>-3 FA) with the main biologically active <italic>n</italic>-3 FAs being eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Consumption of fish and fish oils oil increases the concentration of EPA and DHA in blood, cells and tissues [<xref rid="B11-nutrients-06-04043" ref-type="bibr">11</xref>,<xref rid="B12-nutrients-06-04043" ref-type="bibr">12</xref>] and alters the physical properties of cell membranes and the function of membrane proteins, including receptors, transporters and signalling proteins [<xref rid="B13-nutrients-06-04043" ref-type="bibr">13</xref>,<xref rid="B14-nutrients-06-04043" ref-type="bibr">14</xref>]. <italic>n</italic>-3 FA are incorporated into cell membranes in competition with the more abundant <italic>n</italic>-6 FA, AA, at the expense of the latter. AA may be liberated by phospholipases from cell membranes and induces leucocytes to produce the pro-inflammatory LTB<sub>4</sub> and the side product, 5-hydroxyeicosatetraenoic acid (5-HETE). In contrast, leukotriene B<sub>5</sub> (LTB<sub>5</sub>) and the side product, 5-hydroxyeicosapentaenoic acid (5-HEPE), derived from EPA [<xref rid="B15-nutrients-06-04043" ref-type="bibr">15</xref>], have considerably less potent biological activities in comparison to LTB<sub>4</sub> [<xref rid="B15-nutrients-06-04043" ref-type="bibr">15</xref>,<xref rid="B16-nutrients-06-04043" ref-type="bibr">16</xref>]. Replacement of <italic>n</italic>-6 FA with <italic>n</italic>-3 FA in membranes of immune active cells may therefore lead to reduced formation of pro-inflammatory compounds, and by this, and other [<xref rid="B5-nutrients-06-04043" ref-type="bibr">5</xref>,<xref rid="B12-nutrients-06-04043" ref-type="bibr">12</xref>] mechanisms, <italic>n</italic>-3 FA may decrease infectious complications after surgery [<xref rid="B7-nutrients-06-04043" ref-type="bibr">7</xref>,<xref rid="B17-nutrients-06-04043" ref-type="bibr">17</xref>,<xref rid="B18-nutrients-06-04043" ref-type="bibr">18</xref>,<xref rid="B19-nutrients-06-04043" ref-type="bibr">19</xref>,<xref rid="B20-nutrients-06-04043" ref-type="bibr">20</xref>]. The influence of enteral feeds, including <italic>n</italic>-3 FA on AA-derived eicosanoids (e.g., LTB<sub>4</sub>), has been the subject of much attention [<xref rid="B5-nutrients-06-04043" ref-type="bibr">5</xref>,<xref rid="B21-nutrients-06-04043" ref-type="bibr">21</xref>,<xref rid="B22-nutrients-06-04043" ref-type="bibr">22</xref>,<xref rid="B23-nutrients-06-04043" ref-type="bibr">23</xref>]. Several studies have indicated that <italic>n</italic>-3 FAs modulate the generation of inflammatory eicosanoids in gastrointestinal surgical patients [<xref rid="B24-nutrients-06-04043" ref-type="bibr">24</xref>,<xref rid="B25-nutrients-06-04043" ref-type="bibr">25</xref>,<xref rid="B26-nutrients-06-04043" ref-type="bibr">26</xref>] and may help to counteract the surgery-induced decline in antigen-presenting cell activity [<xref rid="B20-nutrients-06-04043" ref-type="bibr">20</xref>] and T-cell cytokine production [<xref rid="B27-nutrients-06-04043" ref-type="bibr">27</xref>].</p><p>The aim of the present study was to evaluate the production of LTB<sub>4</sub>, 5-HETE, LTB<sub>5</sub> and 5-HEPE from stimulated neutrophils after seven days of preoperative treatment with an <italic>n</italic>-3 FA-enriched oral nutritional supplement (ONS) in patients undergoing colorectal cancer surgery and to study the possible impact on clinical outcome. Furthermore, the correlation between LTB<sub>4</sub> values and postoperative complications was investigated.</p></sec><sec><title>2. Materials and Methods</title><sec><title>2.1. Study Design</title><p>This was a sub-study of a randomized, double-blind, prospective, placebo-controlled single-centre interventional trial involving 148 participants (<xref ref-type="fig" rid="nutrients-06-04043-f001">Figure 1</xref>) awaiting colorectal cancer surgery [<xref rid="B28-nutrients-06-04043" ref-type="bibr">28</xref>]. Participants were recruited consecutively from the outpatient clinic of the Department of Surgical Gastroenterology, Aalborg University Hospital. All eligible participants were asked to participate.</p><p>Exclusion criteria were diabetes mellitus, consumption of &#x0003e;5 alcoholic drinks per day, emergency surgery, inability to understand the spoken and written information in Danish, untreated psychiatric conditions, pregnancy or breast-feeding, reduced kidney function (plasma creatinine &#x0003e; 130 &#x003bc;mol/L), use of <italic>n</italic>-3 FA supplements, anticipated poor compliance, immunosuppressive diseases and participation in another clinical trial.</p><p>After providing oral and written informed consent, participants were randomly assigned to treatment with <italic>n</italic>-3 FA (active treatment) or control (a standard ONS without marine <italic>n</italic>-3 FA), 200 mL twice per day (morning and afternoon) for 7 days before surgery. Randomization was performed using sealed non-transparent envelopes containing the randomization number and kept at the investigation site according to CONSORT (Consolidated Standards of Reporting Trials) guidelines [<xref rid="B29-nutrients-06-04043" ref-type="bibr">29</xref>]. The active and the control ONS cartons looked identical and had identical taste and scent (coffee). The main investigator and a study nurse enrolled the participants at the outpatient clinic and randomly assigned them to active treatment or control. The participants, carers, investigators and other researchers were blinded to treatment allocation throughout the study. The investigators had no access to the code until after completion of the study. Statistical analyses were completed before the code was broken.</p><p>Information collected included demographic data, tumour location and American Society of Anaesthesiologists (ASA) risk score [<xref rid="B30-nutrients-06-04043" ref-type="bibr">30</xref>]. All patients underwent standard Nutritional Risk Screening (NRS 2002) [<xref rid="B31-nutrients-06-04043" ref-type="bibr">31</xref>]. A food questionnaire focusing on consumption of seafood on a monthly basis was completed at baseline. </p><p>The study was approved by the regional ethics committee (N-VN-20050035) and conducted according to the Hong Kong amendment to the Declaration of Helsinki. The trial was registered at ClinicalTrials.gov: ID NCT00488904 [<xref rid="B32-nutrients-06-04043" ref-type="bibr">32</xref>].</p></sec><sec><title>2.2. Intervention</title><p>Participants in the active or control group received the ONS as a sip feed (200 mL twice a day morning and afternoon) for 7 days before surgery. The feeds (Supportan<sup>&#x000ae;</sup>) were isocaloric (1.5 kcal/mL) and isonitrogenous (<xref ref-type="table" rid="nutrients-06-04043-t001">Table 1</xref>) and were provided by Fresenius Kabi (Bad Homburg, Germany). Both feeds contained the same amounts of carbohydrate, protein, total fat and <italic>n-</italic>6 FA (<xref ref-type="table" rid="nutrients-06-04043-t001">Table 1</xref>).</p><fig id="nutrients-06-04043-f001" position="float"><label>Figure 1</label><caption><p>Patient flow through the study.</p></caption><graphic xlink:href="nutrients-06-04043-g001"/></fig><table-wrap id="nutrients-06-04043-t001" position="float"><object-id pub-id-type="pii">nutrients-06-04043-t001_Table 1</object-id><label>Table 1</label><caption><p>Daily intake of energy and nutrients from the <italic>n</italic>-3 FA-enriched and the control oral nutritional supplement.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Daily dose</th><th align="center" valign="middle" rowspan="1" colspan="1">Control</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic>-3 FA (Active)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Energy (kcal)</td><td align="center" valign="middle" rowspan="1" colspan="1">600</td><td align="center" valign="middle" rowspan="1" colspan="1">600</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Protein (g) </td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Carbohydrate (g)</td><td align="center" valign="middle" rowspan="1" colspan="1">49.6</td><td align="center" valign="middle" rowspan="1" colspan="1">49.6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fat (g)</td><td align="center" valign="middle" rowspan="1" colspan="1">26.8</td><td align="center" valign="middle" rowspan="1" colspan="1">26.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">EPA (g)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DHA (g)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total
<italic>n</italic>-6 FA (g)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3</td></tr></tbody></table></table-wrap><p>Fat content of the supplement was comprised of medium chain triglycerides, sunflower oil and safflower oil. The active supplement also contained additional fish oil at a level to achieve 2 g EPA and 1 g DHA per day (<xref ref-type="table" rid="nutrients-06-04043-t001">Table 1</xref>). Participants were provided with the sip feeds at inclusion, to consume twice a day for 7 days at home before hospitalization. A questionnaire regarding compliance preoperatively was completed, and good compliance was defined as self-reported consumption of at least 12 of the 14 ONS cartons before surgery.</p></sec><sec><title>2.3. Isolation of Blood Neutrophils</title><p>Blood was drawn in the fasting state on the day of the surgery. Neutrophils were separated from anticoagulated (K-EDTA 1.6 mg/mL) blood layered on top of PolymorphprepTM (AXIS-SHIELD PoC AS, Rodeloekka, Norway) and separated by a one-step centrifugation technique at 450 g for 40 min. Neutrophils were harvested and washed twice in tissue culture medium (RPMI 1640, Sigma-Aldrich, Ayrshire, UK), at ambient temperature and centrifuged for 10 min at 520&#x000d7; <italic>g</italic>. Subsequently, neutrophils were counted and red cells eliminated by the addition of ice-cold 0.2% saline for 35 s. Next, 1.6% ice-cold saline was added in order to obtain an isotonic 0.9% concentration, followed by centrifugation at 300&#x000d7; <italic>g</italic> at 5 &#x000b0;C for 5 min, which was repeated once. Neutrophils were then washed in a phosphate buffer containing glucose and human albumin (PBS) and resuspended in PBS adjusting the concentration to 1 &#x000d7; 10<sup>7</sup> neutrophils/mL PBS. Isolated neutrophils were stored at &#x02212;80 &#x000b0;C until analysis.</p></sec><sec><title>2.4. Analysis of Leukotrienes, 5-HEPE and 5-HETE</title><p>The neutrophil suspension (0.9 mL of 1 &#x000d7; 10<sup>7</sup> granulocytes/mL PBS) was prewarmed to 37 &#x000b0;C, and CaCl<sub>2</sub>, MgCl<sub>2</sub> and calcium ionophore (A23187) at a final concentration of 10 &#x000b5;M were added to initiate stimulation. After 10 min, the reaction was terminated by the addition of 100% ice-cold ethanol, and the mixtures were centrifuged at 4 &#x000b0;C at 700&#x000d7; <italic>g</italic>. The supernatant was stored at &#x02212;80 &#x000b0;C for later analysis. C18 cartridges (Sep-Pak VAC RC, Waters Co., Milford, MA, USA) were used for the extraction of leukotrienes (LT), 5-HEPE and 5-HETE. The ethanol mixture was thawed and centrifuged, and international standard prostaglandin B<sub>2</sub> (PGB<sub>2</sub>) and trifluoroacetic acid were added. The cartridges were conditioned and equilibrated using methyl formate, 100% ethanol and water. The acidified sample was loaded onto the cartridge, washed with 15% ethanol, water and hexane and eluted with methyl formate. The solvent was evaporated to dryness under nitrogen, and the sediment was dissolved in the mobile phase (31% H<sub>2</sub>O, 27% methanol, 42% acetonitrile and 0.025% trifluoroacetic acid).</p><p>Analysis was performed by high pressure liquid chromatography (Dionex Ultimate LPG-3400A) on an Acclaim RSLC 2.1 mm &#x000d7; 100 mm C18 column (Dionex Corporation, Sunnyvale, CA, USA). Concentrations were calculated using the internal standard and response factors. The response factors were calculated by analysis of a non-stimulated neutrophil suspension after the addition of known amounts of standards of LTB<sub>4</sub>, LTB<sub>5</sub>, 5-HETE and 5-HEPE, as well as an internal standard (PGB<sub>2</sub>). Samples were extracted and analysed using high performance liquid chromatography, and eventually, the recovery factors were calculated.</p></sec><sec><title>2.5. Granulocyte Fatty Acid Analysis</title><p>Blood was drawn in the fasting state on the day of surgery. Granulocytes were prepared as described previously [<xref rid="B33-nutrients-06-04043" ref-type="bibr">33</xref>]. FA profiles were determined by gas chromatography using a Varian 3900 gas chromatograph, CP-8400 autosampler and CP 8414 autoinjector (Varian, Middelburg, The Netherlands), as well as a flame ionization detector. In split injection mode, a CP-sil 88.60-m &#x000d7; 0.25-mm capillary column (Varian, Middelburg, The Netherlands), temperature programming from 90 to 205 &#x000b0;C, a constant flow rate of 1.0 mL/min and helium carrier gas were used. Results for individual FAs are expressed as a percentage of the total FA content.</p></sec><sec><title>2.6. Statistical Analysis</title><p>The basic characteristics of the trial population were analysed with Fisher&#x02019;s exact test for categorical variables and unpaired <italic>t</italic>-tests for continuous variables. Differences between treatment groups were analysed using unpaired <italic>t</italic>-tests. If variances differed between groups, Welch&#x02019;s approximation was used. The distribution of continuous data was analysed for normality. As the values for 5-HEPE, 5-HETE and LTs were right skewed distributed, log transformed observations were analysed, and these were normally distributed. Distributions of 5-HEPE, 5-HETE and LT were described with median and inter-quartile range (IQR). Relative differences between groups in medians were calculated by exponentiation of the differences between log-transformed means. Associations between LTB<sub>4</sub> values and postoperative complications were analysed using logistic regression. The associations between log-transformed LT values 5-HEPE and AA, EPA and AA/EPA were analysed using linear regression. Analyses were performed blinded to treatment groups. The active and control groups were not identified until after the statistical analyses had been conducted. All <italic>p</italic>-values were two-tailed, and differences were reported with 95% confidence intervals (CI). <italic>p</italic>-values below 0.05 were considered significant. All analyses were performed using Stata version 11.2 (StataCorp, 2009; Texas City, TX, USA).</p></sec></sec><sec><title>3. Results</title><sec sec-type="subjects"><title>3.1. Participants Characteristics</title><p>All eligible participants (<italic>n</italic> = 610) were asked to participate, but 230 participants were not included. This was due to a change in clinical practice during the study, such that many patients were offered surgery within a five-day period, which did not allow for participants to complete the seven-day intervention. Furthermore, some participants did not meet the inclusion criteria (201), and 31 participants declined to participate. Baseline characteristics of the included <italic>vs.</italic> the non-included participants did not differ.</p><p>A total of 148 consecutive patients (68 females, 80 males; mean age 71 (range 41&#x02013;89) years) were included in the study. The majority of participants had open surgery; laparoscopic resection was only performed in nine patients in the control group and nine in the <italic>n</italic>-3 FA group. Participant characteristics did not differ between treatment groups (<xref ref-type="table" rid="nutrients-06-04043-t002">Table 2</xref>).</p><table-wrap id="nutrients-06-04043-t002" position="float"><object-id pub-id-type="pii">nutrients-06-04043-t002_Table 2</object-id><label>Table 2</label><caption><p>Characteristics of patients in the control and active groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1">Variable</th><th align="center" valign="top" rowspan="1" colspan="1">Control (<italic>n</italic> = 74)</th><th align="center" valign="top" rowspan="1" colspan="1">Active (<italic>n</italic> = 74)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Demographic data</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (10)</td><td align="center" valign="top" rowspan="1" colspan="1">69 (11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.164</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (male/female)</td><td align="center" valign="top" rowspan="1" colspan="1">36/38</td><td align="center" valign="top" rowspan="1" colspan="1">44/30</td><td align="center" valign="top" rowspan="1" colspan="1">0.248</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body weight, kg, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">76 (19)</td><td align="center" valign="top" rowspan="1" colspan="1">77(17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.570</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height, cm, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">169 (11)</td><td align="center" valign="top" rowspan="1" colspan="1">171 (9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.301</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.651</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight loss * (<italic>n</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">0.068</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Clinical characteristics</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking/non-smoking (<italic>n</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">11/60</td><td align="center" valign="top" rowspan="1" colspan="1">17/54</td><td align="center" valign="top" rowspan="1" colspan="1">0.292</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unknown smoking status</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Cancer location</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Colon/rectum (<italic>n</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">40/34</td><td align="center" valign="top" rowspan="1" colspan="1">38/36</td><td align="center" valign="top" rowspan="1" colspan="1">0.869</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Surgical procedure</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">0.977</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Right hemicolectomy + transverse colon (<italic>n</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Left hemicolectomy + sigmoid colon (n)</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Laparoscopic resection of sigmoid colon (<italic>n</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Low anterior resection of rectum or abdominoperineal resection</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Colectomy (<italic>n</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other rectum resection (n)</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Nutritional status **</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">
</td><td align="center" valign="top" rowspan="1" colspan="1">0.089</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No risk (NRS score &#x0003c;3) (<italic>n</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">At risk (NRS score &#x02265;3) (<italic>n</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">39</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unknown (<italic>n</italic>)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: There were no significant differences between groups (<italic>p</italic> &#x0003e; 0.068); BMI, body mass index; * defined as loss of more than 5% of body weight; ** defined according to NRS 2002 [<xref rid="B31-nutrients-06-04043" ref-type="bibr">31</xref>].</p></fn></table-wrap-foot></table-wrap></sec><sec><title>3.2. Fatty Acid Composition of Neutrophils</title><p>Neutrophil EPA and DHA were significantly higher, and AA and linoleic acid was significantly lower in the group receiving <italic>n</italic>-3 FA than in the control group (<xref ref-type="table" rid="nutrients-06-04043-t003">Table 3</xref>) [<xref rid="B28-nutrients-06-04043" ref-type="bibr">28</xref>]. </p><p>The food questionnaire indicated an average dietary intake of <italic>n</italic>-3 FA of 0.6 g per day, with no difference in preoperative intake between groups (<italic>p</italic> = 0.770). None of the included participants received more than 150 mg of anti-inflammatory drugs daily. Both supplements were well tolerated with no adverse effects reported. Nine participants randomized to active treatment and 10 participants in the control group did not receive the allocated intervention for reasons listed in <xref ref-type="fig" rid="nutrients-06-04043-f001">Figure 1</xref>.</p><p>Preoperatively, 63 of 65 participants in the active group were compliant compared with 56 of 64 participants in the control group (<italic>p</italic> = 0.266). Two participants died in each group. In the active group, death was caused by pneumonia and a myocardial infarction, whereas the participants in the control group died from septicaemia and sudden cardiac death.</p><table-wrap id="nutrients-06-04043-t003" position="float"><object-id pub-id-type="pii">nutrients-06-04043-t003_Table 3</object-id><label>Table 3</label><caption><p>Granulocyte fatty acids on day of operation in the control and active groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="top" colspan="1">
</th><th style="border-bottom:solid thin" colspan="2" align="center" valign="bottom" rowspan="1">Weight% of Total FA Content </th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Control</th><th align="center" valign="top" rowspan="1" colspan="1">Active</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">EPA</td><td align="center" valign="top" rowspan="1" colspan="1">0.54 (0.42&#x02013;0.74)</td><td align="center" valign="top" rowspan="1" colspan="1">2.10 (1.83&#x02013;2.55) *</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">DPA</td><td align="center" valign="top" rowspan="1" colspan="1">0.54 (0.42&#x02013;0.74)</td><td align="center" valign="top" rowspan="1" colspan="1">2.11 (1.83&#x02013;2.55) *</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">DHA</td><td align="center" valign="top" rowspan="1" colspan="1">1.31 (1.10&#x02013;1.57)</td><td align="center" valign="top" rowspan="1" colspan="1">1.61 (1.34&#x02013;1.84) *</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Total
<italic>n</italic>-3 FA</td><td align="center" valign="top" rowspan="1" colspan="1">2.44 (1.98&#x02013;2.97)</td><td align="center" valign="top" rowspan="1" colspan="1">5.95 (5.20&#x02013;6.75) *</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Arachidonic acid</td><td align="center" valign="top" rowspan="1" colspan="1">12.51 (11.65&#x02013;13.19)</td><td align="center" valign="top" rowspan="1" colspan="1">11.61 (10.67&#x02013;12.48) *</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">Linoleic acid</td><td align="center" valign="top" rowspan="1" colspan="1">8.94 (8.24&#x02013;9.49)</td><td align="center" valign="top" rowspan="1" colspan="1">9.42 (8.72&#x02013;10.19) **</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: Values are the median (IQR); FA, fatty acid; ONS, oral nutritional supplement; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid; * <italic>p</italic> &#x0003c; 0.001; ** <italic>p</italic> &#x0003c; 0.05 <italic>versus</italic> the control group.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>3.3. Production of Mediators from Neutrophils</title><p>Furthermore, compared to neutrophils from controls, those from participants in the <italic>n</italic>-3 FA group showed a significantly higher (by 176% and 306%, respectively) production of LTB<sub>5</sub> (<italic>p</italic> &#x0003c; 0.001) and 5-HEPE (<italic>p</italic> &#x0003c; 0.001) (<xref ref-type="table" rid="nutrients-06-04043-t004">Table 4</xref>).</p><table-wrap id="nutrients-06-04043-t004" position="float"><object-id pub-id-type="pii">nutrients-06-04043-t004_Table 4</object-id><label>Table 4</label><caption><p>Formation of leukotrienes (LT) and side products (5-HEPE; 5-HETE) from activated neutrophils according to treatment group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Eicosanoids</th><th align="center" valign="middle" rowspan="1" colspan="1">Control</th><th align="center" valign="middle" rowspan="1" colspan="1">Active</th><th align="center" valign="middle" rowspan="1" colspan="1">% Difference</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">LTB<sub>5</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">5.8 (4.9&#x02013;7.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">17.5 (13.5&#x02013;22.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">176 *** (143&#x02013;215)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LTB<sub>4</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">186.8 (156.8&#x02013;230.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">163.5 (136.6&#x02013;199.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;12 *** (&#x02212;21&#x02013;&#x02212;3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5-HETE </td><td align="center" valign="middle" rowspan="1" colspan="1">293.1 (246.5&#x02013;357.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">273.7 (221.8&#x02013;320.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;7 * (&#x02212;14&#x02013;&#x02212;0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5-HEPE </td><td align="center" valign="middle" rowspan="1" colspan="1">34.2 (25.7&#x02013;55.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">154.7 (122.4&#x02013;190.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">306 *** (255&#x02013;364)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LTB<sub>4</sub>/LTB<sub>5</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">31.8 (25.0&#x02013;40.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.6 (7.8&#x02013;11.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;68*** (&#x02212;72&#x02013;&#x02212;65)</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: Data are the median (IQR) ng/10<sup>7</sup> neutrophils and the percentage of difference between estimated medians; *** indicates <italic>p</italic> &#x0003c; 0.01; * indicates <italic>p</italic> &#x0003c; 0.1; ng/10<sup>7</sup> = nanogram/10<sup>7</sup> neutrophils.</p></fn></table-wrap-foot></table-wrap><p>Conversely, in the active group, neutrophils showed a significantly lower (by 12%) production of LTB<sub>4</sub> (<italic>p</italic> &#x0003c; 0.001) and a trend towards lower (by 7%) production of 5-HETE (<italic>p</italic> = 0.059). LTB<sub>4</sub>/LTB<sub>5</sub> was significantly different between groups (by 68%) (<italic>p</italic> &#x0003c; 0.001) (<xref ref-type="table" rid="nutrients-06-04043-t004">Table 4</xref>). There was no statistically significant difference in clinical outcomes (total number of complications, infectious complications, non-infectious complications, intensive care unit stay, mortality, readmissions and hospital stay) between groups, as reported previously [<xref rid="B28-nutrients-06-04043" ref-type="bibr">28</xref>].</p><p>There was no statistically significant association between the values of the proinflammatory LTB<sub>4</sub> production and any clinical outcome, including total number of complications (<italic>p</italic> = 0.524), infectious complications (<italic>p</italic> = 0.660) and non-infectious complications (<italic>p</italic> = 0.307) (<xref ref-type="table" rid="nutrients-06-04043-t005">Table 5</xref>). The ratio LTB<sub>4</sub>/LTB<sub>5</sub> did not have a statistically significant association with the total number of complications (<italic>p</italic> = 0.707), infectious complications (<italic>p</italic> = 0.711) and non-infectious complications (<italic>p</italic> = 0.143) (<xref ref-type="table" rid="nutrients-06-04043-t004">Table 4</xref>).</p><p>However, There were strong associations between the content of AA and EPA in neutrophils and production of LTB<sub>4</sub> and LTB<sub>5</sub> (<xref ref-type="fig" rid="nutrients-06-04043-f002">Figure 2</xref>) (all <italic>p</italic> &#x0003c; 0.01).</p><p>These graphs illustrate that the higher the content of EPA in the cell membranes, the higher the production of LTB<sub>5</sub>. Furthermore, it can be seen that the higher the content of AA in cell membranes, the lower the production of LTB<sub>5</sub>. Furthermore, there were strong associations between AA/EPA in neutrophils and LTB<sub>4</sub> and LTB<sub>5</sub> production (both <italic>p</italic> &#x0003c; 0.01) (results not shown) and between AA, EPA, AA/EPA and 5-HEPE production (all <italic>p</italic> &#x0003c; 0.001) (results not shown).</p><fig id="nutrients-06-04043-f002" position="float"><label>Figure 2</label><caption><p>Associations between log-transformed AAg (AA content in the cell membranes of the granulocytes) and EPAg (EPA content in the cell membranes of the granulocytes) in the neutrophils, as well as the formation of LTs (LTB<sub>4</sub> and LTB<sub>5</sub> (ng/10<sup>7</sup>)) by neutrophils, illustrated using scatter plots with regression lines and confidence bands added. Control group, red dots; active group, blue dots.</p></caption><graphic xlink:href="nutrients-06-04043-g002"/></fig><table-wrap id="nutrients-06-04043-t005" position="float"><object-id pub-id-type="pii">nutrients-06-04043-t005_Table 5</object-id><label>Table 5</label><caption><p>Associations between LTs production by neutrophils and clinical outcome described by odds ratio (OR), CI and <italic>p</italic>-values for a unit change in LTB<sub>4</sub> and LTB<sub>4</sub>/LTB<sub>5</sub>, respectively.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="top" colspan="1">
</th><th style="border-bottom:solid thin" colspan="3" align="center" valign="top" rowspan="1">LTB<sub>4</sub></th><th style="border-bottom:solid thin" colspan="3" align="center" valign="top" rowspan="1">LTB<sub>4</sub>/LTB<sub>5</sub></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">OR</th><th align="center" valign="middle" rowspan="1" colspan="1">CI</th><th align="center" valign="middle" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="middle" rowspan="1" colspan="1">OR</th><th align="center" valign="middle" rowspan="1" colspan="1">CI</th><th align="center" valign="middle" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Infectious complications</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00&#x02013;1.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.660</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97&#x02013;1.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.711</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Non-infectious complications</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99&#x02013;1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.307</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98</td><td align="center" valign="middle" rowspan="1" colspan="1">0.94&#x02013;1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.143</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total number of complications</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99&#x02013;1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.524</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98&#x02013;1.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.707</td></tr></tbody></table></table-wrap></sec></sec><sec><title>4. Discussion</title><p>In this prospective randomized, double-blind, single-centre, placebo controlled study, it was demonstrated that seven days of enteral supplementation with 3 g of EPA + DHA daily resulted in a higher neutrophil production of LTB<sub>5</sub> and a lower production of LTB<sub>4</sub> compared to the control group. In addition, there was a higher neutrophil 5-HEPE production and a trend to lower production of 5-HETE in the active group compared to the control. While the differences in LTB<sub>4</sub> and LTB<sub>5</sub> production indicate an anti-inflammatory action of the supplement, it is unknown whether the difference in formation of 5-HETE and 5-HEPE between groups is of clinical relevance. However, 5-HETE enhances lymphocyte proliferation, whereas 5-HEPE only has one-tenth the potency of 5-HETE regarding this [<xref rid="B34-nutrients-06-04043" ref-type="bibr">34</xref>]. Thus, the current study demonstrates that preoperative supplementation with <italic>n</italic>-3 FA for one week can modulate immune function, assessed as the production of lipoxygenase mediators, in participants admitted for elective colorectal cancer surgery. However, this was not associated with a decrease in postoperative complication rates [<xref rid="B28-nutrients-06-04043" ref-type="bibr">28</xref>].</p><p>The strengths of the present study are that it was a randomized, prospective, relatively large clinical study, was double-blind, with an identical appearance for the sip feed cartons, the taste of <italic>n</italic>-3 FA was undetectable and that compliance was acceptable. Furthermore, the study population was relatively homogenous.</p><p>One limitation of the present study is that we only had data on eicosanoid formation from the day of surgery, whereas postoperative changes would also have been of interest. The short duration of the intervention (seven days) may have limited the incorporation of <italic>n</italic>-3 FA and the decrease of AA in neutrophils and, thereby, limited the impact on LTB<sub>4</sub> production, but a longer period of supplementation was not possible, as participants were operated on soon after cancer diagnosis. However, we showed in earlier publications that 3 g of <italic>n</italic>-3 FA for seven days before surgery was sufficient to assure significant incorporation of <italic>n</italic>-3 FA into neutrophils and into colonic tissue [<xref rid="B28-nutrients-06-04043" ref-type="bibr">28</xref>,<xref rid="B35-nutrients-06-04043" ref-type="bibr">35</xref>]. The required sample size was based on a reduction in postoperative infection rates from 30% to 10% and was calculated to be 148 participants in all, but we were only able to analyse data from 129 of these. A final limitation is the discrepancy between the number of eligible (610) and analysed participants (129) due to a change in clinical practice during the study, such that many patients were offered surgery within a five-day period, which did not allow for participants to complete the seven-day intervention.</p><p>Our findings are consistent with the results from three recent studies in humans [<xref rid="B24-nutrients-06-04043" ref-type="bibr">24</xref>,<xref rid="B36-nutrients-06-04043" ref-type="bibr">36</xref>,<xref rid="B37-nutrients-06-04043" ref-type="bibr">37</xref>]. In a prospective double-blind study, Wang <italic>et al.</italic> [<xref rid="B37-nutrients-06-04043" ref-type="bibr">37</xref>] randomized 64 participants with a need for postoperative parenteral nutrition after surgery into two groups. The study population was a mix of surgical patients (22 gastric cancers; 29 colonic cancers; 13 with other digestive diseases). They received either fish oil containing lipid emulsion (a mixture of soybean oil, MCT and fish oil) as part of the intravenous regimen, or a mix of soybean oil and MCT for 5 days after surgery. There was a significant increase in the neutrophil LTB<sub>5</sub>/LTB<sub>4</sub> ratio but no effect on clinical outcome, infectious complications and bleeding events. Grimm <italic>et al.</italic> [<xref rid="B36-nutrients-06-04043" ref-type="bibr">36</xref>] randomized 33 participants undergoing major abdominal surgery into two groups in a prospective double-blind study to receive parenteral nutrition providing either a fish oil containing lipid emulsion (a mixture of soybean oil, MCT, olive oil and fish oil) or soybean oil for five days after surgery. The study population was again a mix of surgical patients. The initial production of LTB<sub>4</sub> and LTB<sub>5</sub> by neutrophils was similar in both groups. The production of LTB<sub>5</sub> from neutrophils was significantly increased, and the release of LTB<sub>4</sub> was decreased, though not significantly, in the participants receiving fish oil. The length of hospital stay was significantly shorter in the intervention group. Finally, K&#x000f6;ller <italic>et al.</italic> [<xref rid="B24-nutrients-06-04043" ref-type="bibr">24</xref>] conducted a prospective double-blind randomized study with 30 participants undergoing colorectal surgery. Participants received parenteral nutrition, providing either a fish oil containing lipid emulsion (a mixture of soybean oil, MCT and fish oil) or soybean oil for five days post-surgery. This study also found a significant increase in LTB<sub>5</sub> production by leukocytes in the fish oil group, but without a concomitant decrease in LTB<sub>4</sub> production. These three studies all made use of intravenous (IV) nutrition given postoperatively. The present study, which used enteral nutrition given preoperatively, agrees with these earlier findings of increased LTB<sub>5</sub> production and decreased LTB<sub>4</sub> production after fish oil provision, but with limited clinical impact.</p><p>Some earlier studies have reported beneficial effects of oral <italic>n</italic>-3 FA supplementation in gastrointestinal surgery patients. Wachtler <italic>et al.</italic> [<xref rid="B26-nutrients-06-04043" ref-type="bibr">26</xref>] analysed leukocyte function in 40 participants undergoing major upper gastrointestinal surgery in a placebo-controlled double-blind study. One group received an <italic>n</italic>-3 FA-enriched (0.33 g/100 mL) oral supplement, also containing arginine and ribonucleic acid, and the other group received a standard control supplement for five days preoperatively. There was a significantly higher production of LTB<sub>5</sub> from neutrophils in the intervention group when compared to controls. However, no changes in LTB<sub>4</sub> were evident in the intervention group. The authors reported a low number of postoperative complications. In another study, Shimizu <italic>et al.</italic> [<xref rid="B38-nutrients-06-04043" ref-type="bibr">38</xref>] gave 12 children with ulcerative colitis 1.8 g EPA orally per day for two months. LTB<sub>4</sub> production by leucocytes and colonic mucosa were assessed before and after the intervention. Biopsies were taken from the rectal mucosa during sigmoidoscopy before and after initiation of EPA supplementation. After two months of supplementation, there was a decrease in LTB<sub>4</sub> production by leucocytes and colonic mucosa, while no information regarding LTB<sub>5</sub> production was given.</p><p>IV administration of <italic>n</italic>-3 FA ensures a quicker incorporation of the presumed active substances (<italic>n</italic>-3 FA) into the membranes of immune cells [<xref rid="B39-nutrients-06-04043" ref-type="bibr">39</xref>,<xref rid="B40-nutrients-06-04043" ref-type="bibr">40</xref>]. However, this format is not feasible in the pre-operative setting. ONSs are less expensive and enable the use of the gut prior to surgery. Two studies providing IV <italic>n</italic>-3 FA for five days post-operatively did not show any decrease in the production of LTB<sub>4</sub> [<xref rid="B24-nutrients-06-04043" ref-type="bibr">24</xref>,<xref rid="B36-nutrients-06-04043" ref-type="bibr">36</xref>]. Importantly many of these studies did not provide explicit information about the amount of <italic>n</italic>-3 FA given. </p><p>In the present study, seven days of oral supplementation with 3 g of <italic>n</italic>-3 FA daily ensured significant incorporation of EPA into neutrophils and a significant decrease in the formation of LTB<sub>4</sub>. However, to achieve an anti-inflammatory response meditated by <italic>n</italic>-3 FA, it is probably more important that the formation of the AA-derived LTB<sub>4</sub> is suppressed than an increase in LTB<sub>5</sub>. Despite this, there was no effect on clinical outcome in the current study. One explanation for this may be that <italic>n</italic>-3 FA incorporation was not sufficiently high. A higher <italic>n</italic>-3 FA dose or a longer duration of intervention could have had an impact on clinical outcome. The ratio LTB<sub>4</sub>/LTB<sub>5</sub> was 68% lower in the active group, which is a considerable decrease, but still did not have any effect on clinical outcome. </p><p>One other important factor may be that the nutritional status of the patients, evaluated by NRS 2002, was generally good for most participants. A weight loss of more than 5% of body weight was only detected in 23% of participants entering the study. This could account for the lack of clinical improvement with the <italic>n</italic>-3 FA-enriched ONS, since it is likely that malnourished participants might benefit the most from ONS and from oral <italic>n</italic>-3 FA.</p></sec><sec><title>5. Conclusions</title><p>In summary, the current study shows that an ONS providing 3 g of <italic>n</italic>-3 FA daily for seven days before surgery was able to induce a significant decrease in the formation of the pro-inflammatory LTB<sub>4</sub> from neutrophils with a simultaneous increased production of LTB<sub>5</sub>. A decrease in the formation of 5-HETE, though not significant, and a significant rise in 5-HEPE was also seen. However, the clinical consequences of these changes are unknown. Associations between values of LTB<sub>4</sub> or LTB<sub>4</sub>/LTB<sub>5</sub> and postoperative complication rates were not seen. This indicates either that the changes observed were too small or that the formation of LTs from activated neutrophils is not an important determinant of surgical complications. Whether a longer period (months) of <italic>n</italic>-3 FA intake could be of a benefit for patients operated on for colorectal cancer regarding shorter stay in hospital or longer survival needs to be investigated in larger trials.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was kindly supported by Fresenius Kabi (Bad Homburg, Germany), The Obelske Family Foundation, the Hoejmosegaard Grant, the Aase and Ejnar Danielsens Foundation and the North Jutland Medical Association.</p><p>We thank study nurse Anne Madsen and the staff at the Lipid Research Clinic at Aalborg University Hospital for invaluable assistance in connection with completion of the study. We also thank Hanne Madsen for proofreading.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>AA</term><def><p>arachidonic acid</p></def></def-item><def-item><term>ASA</term><def><p>American Society of Anaesthesiologists</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>CI</term><def><p>confidence intervals</p></def></def-item><def-item><term>DHA</term><def><p>docosahexaenoic acid</p></def></def-item><def-item><term>EPA</term><def><p>eicosapentaenoic acid</p></def></def-item><def-item><term>5-HEPE</term><def><p>5-hydroxyeicosapentaenoic acid</p></def></def-item><def-item><term>5-HETE</term><def><p>5-hydroxyeicosatetraenoic acid</p></def></def-item><def-item><term>IV</term><def><p>intravenous;</p></def></def-item><def-item><term>IQR</term><def><p>inter-quartile range</p></def></def-item><def-item><term>LT</term><def><p>leukotrienes</p></def></def-item><def-item><term>LTB<sub>4</sub></term><def><p>leukotriene B<sub>4</sub></p></def></def-item><def-item><term>LTB<sub>5</sub></term><def><p>leukotriene B<sub>5</sub></p></def></def-item><def-item><term><italic>n</italic>-3 FA</term><def><p><italic>n</italic>-3 fatty acids</p></def></def-item><def-item><term><italic>n</italic>-6 FA</term><def><p><italic>n</italic>-6 fatty acids</p></def></def-item><def-item><term>MCT</term><def><p>medium-chain triglycerides</p></def></def-item><def-item><term>ng</term><def><p>nanograms</p></def></def-item><def-item><term>NRS 2002</term><def><p>Nutritional Risk Screening</p></def></def-item><def-item><term>ONS</term><def><p>oral nutritional supplement</p></def></def-item><def-item><term>OR</term><def><p>odds ratio</p></def></def-item><def-item><term>PBS</term><def><p>phosphate-buffered saline</p></def></def-item><def-item><term>PGB<sub>2</sub></term><def><p>prostaglandin B<sub>2</sub></p></def></def-item></def-list></glossary><notes><title>Author Contributions</title><p>Lone Schmidt Sorensen: study concept and design; acquisitions of data; analysis and interpretations of data; drafting of the manuscript; statistical analysis; obtained funding; study supervision; approval of the final version of the manuscript.</p><p>Henrik Hojgaard Rasmussen: study concept and design; critical revision of the manuscript; study supervision; approval of the final version of the manuscript.</p><p>S&#x000f8;ren Lundbye-Christensen: statistical support; critical revision of the manuscript; approval of the final version of the manuscript.</p><p>Ole Thorlacius-Ussing: study concept and design; critical revision of the manuscript; study supervision; approval of the final version of the manuscript.</p><p>Karen Lindorff-Larsen: study concept and design; acquisitions of data; critical revision of the manuscript; study supervision; approval of the final version of the manuscript.</p><p>Erik Berg Schmidt: study concept and design; critical revision of the manuscript; study supervision; approval of the final version of the manuscript.</p><p>Philip C. Calder: study concept and design; critical revision of the manuscript; approval of the final version of the manuscript.</p></notes><notes><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-nutrients-06-04043"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Platt</surname><given-names>J.J.</given-names></name><name><surname>Ramanathan</surname><given-names>M.L.</given-names></name><name><surname>Crosbie</surname><given-names>R.A.</given-names></name><name><surname>Anderson</surname><given-names>J.H.</given-names></name><name><surname>McKee</surname><given-names>R.F.</given-names></name><name><surname>Horgan</surname><given-names>P.G.</given-names></name><name><surname>McMillan</surname><given-names>D.C.</given-names></name></person-group>
<article-title>C-reactive protein as a predictor of postoperative infective complications after curative resection in patients with colorectal cancer</article-title>
<source>Ann. Surg. Oncol.</source>
<year>2012</year>
<volume>19</volume>
<fpage>4168</fpage>
<lpage>4177</lpage>
<pub-id pub-id-type="doi">10.1245/s10434-012-2498-9</pub-id>
<pub-id pub-id-type="pmid">22805866</pub-id></element-citation></ref><ref id="B2-nutrients-06-04043"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M.W.</given-names></name><name><surname>Tang</surname><given-names>D.N.</given-names></name><name><surname>Hou</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>J.M.</given-names></name><name><surname>Hua</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>J.H.</given-names></name><name><surname>Cui</surname><given-names>H.Y.</given-names></name></person-group>
<article-title>Impact of fish oil enriched total parenteral nutrition on elderly patients after colorectal cancer surgery</article-title>
<source>Chin. Med. J. (Engl.)</source>
<year>2012</year>
<volume>125</volume>
<fpage>178</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="pmid">22340541</pub-id></element-citation></ref><ref id="B3-nutrients-06-04043"><label>3.</label><element-citation publication-type="webpage">
<article-title>The Danish Colorectal Cancer Database, The Danish Colorectal Cancer Group. Annual review</article-title>
<comment>Available online:<ext-link ext-link-type="uri" xlink:href="http://www.dccg.dk/03_Publikation/02_arsraport_pdf/aarsrapport_2011.pdf">http://www.dccg.dk/03_Publikation/02_arsraport_pdf/aarsrapport_2011.pdf</ext-link></comment>
<date-in-citation>(accessed on 3 April 2013)</date-in-citation>
</element-citation></ref><ref id="B4-nutrients-06-04043"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kehlet</surname><given-names>H.</given-names></name><name><surname>Dahl</surname><given-names>J.B.</given-names></name></person-group>
<article-title>Anaesthesia, surgery, and challenges in postoperative recovery</article-title>
<source>Lancet</source>
<year>2003</year>
<volume>362</volume>
<fpage>1921</fpage>
<lpage>1928</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(03)14966-5</pub-id>
<pub-id pub-id-type="pmid">14667752</pub-id></element-citation></ref><ref id="B5-nutrients-06-04043"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calder</surname><given-names>P.C.</given-names></name></person-group>
<article-title><italic>n</italic>-3 fatty acids, inflammation, and immunity&#x02014;Relevance to postsurgical and critically ill patients</article-title>
<source>Lipids</source>
<year>2004</year>
<volume>39</volume>
<fpage>1147</fpage>
<lpage>1161</lpage>
<pub-id pub-id-type="doi">10.1007/s11745-004-1342-z</pub-id>
<pub-id pub-id-type="pmid">15736910</pub-id></element-citation></ref><ref id="B6-nutrients-06-04043"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bozzetti</surname><given-names>F.</given-names></name><name><surname>Braga</surname><given-names>M.</given-names></name><name><surname>Gianotti</surname><given-names>L.</given-names></name><name><surname>Gavazzi</surname><given-names>C.</given-names></name><name><surname>Mariani</surname><given-names>L.</given-names></name></person-group>
<article-title>Postoperative enteral <italic>versus</italic> parenteral nutrition in malnourished patients with gastrointestinal cancer: A randomised multicentre trial</article-title>
<source>Lancet</source>
<year>2001</year>
<volume>358</volume>
<fpage>1487</fpage>
<lpage>1492</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(01)06578-3</pub-id>
<pub-id pub-id-type="pmid">11705560</pub-id></element-citation></ref><ref id="B7-nutrients-06-04043"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braga</surname><given-names>M.</given-names></name><name><surname>Gianotti</surname><given-names>L.</given-names></name><name><surname>Vignali</surname><given-names>A.</given-names></name><name><surname>Carlo</surname><given-names>V.D.</given-names></name></person-group>
<article-title>Preoperative oral arginine and <italic>n</italic>-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer</article-title>
<source>Surgery</source>
<year>2002</year>
<volume>132</volume>
<fpage>805</fpage>
<lpage>814</lpage>
<pub-id pub-id-type="doi">10.1067/msy.2002.128350</pub-id>
<pub-id pub-id-type="pmid">12464864</pub-id></element-citation></ref><ref id="B8-nutrients-06-04043"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gustafsson</surname><given-names>U.O.</given-names></name><name><surname>Ljungqvist</surname><given-names>O.</given-names></name></person-group>
<article-title>Perioperative nutritional management in digestive tract surgery</article-title>
<source>Curr. Opin. Clin. Nutr. Metab. Care</source>
<year>2011</year>
<volume>14</volume>
<fpage>504</fpage>
<lpage>509</lpage>
<pub-id pub-id-type="doi">10.1097/MCO.0b013e3283499ae1</pub-id>
<pub-id pub-id-type="pmid">21760503</pub-id></element-citation></ref><ref id="B9-nutrients-06-04043"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jie</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>Z.M.</given-names></name><name><surname>Nolan</surname><given-names>M.T.</given-names></name><name><surname>Zhu</surname><given-names>S.N.</given-names></name><name><surname>Yu</surname><given-names>K.</given-names></name><name><surname>Kondrup</surname><given-names>J.</given-names></name></person-group>
<article-title>Impact of preoperative nutritional support on clinical outcome in abdominal surgical patients at nutritional risk</article-title>
<source>Nutrition</source>
<year>2012</year>
<volume>28</volume>
<fpage>1022</fpage>
<lpage>1027</lpage>
<pub-id pub-id-type="doi">10.1016/j.nut.2012.01.017</pub-id>
<pub-id pub-id-type="pmid">22673593</pub-id></element-citation></ref><ref id="B10-nutrients-06-04043"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryan</surname><given-names>A.M.</given-names></name><name><surname>Reynolds</surname><given-names>J.V.</given-names></name><name><surname>Healy</surname><given-names>L.</given-names></name><name><surname>Byrne</surname><given-names>M.</given-names></name><name><surname>Moore</surname><given-names>J.</given-names></name><name><surname>Brannelly</surname><given-names>N.</given-names></name><name><surname>McHugh</surname><given-names>A.</given-names></name><name><surname>McCormack</surname><given-names>D.</given-names></name><name><surname>Flood</surname><given-names>P.</given-names></name></person-group>
<article-title>Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: Results of a double-blinded randomized controlled trial</article-title>
<source>Ann. Surg.</source>
<year>2009</year>
<volume>249</volume>
<fpage>355</fpage>
<lpage>363</lpage>
<pub-id pub-id-type="doi">10.1097/SLA.0b013e31819a4789</pub-id>
<pub-id pub-id-type="pmid">19247018</pub-id></element-citation></ref><ref id="B11-nutrients-06-04043"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Senkal</surname><given-names>M.</given-names></name><name><surname>Haaker</surname><given-names>R.</given-names></name><name><surname>Linseisen</surname><given-names>J.</given-names></name><name><surname>Wolfram</surname><given-names>G.</given-names></name><name><surname>Homann</surname><given-names>H.H.</given-names></name><name><surname>Stehle</surname><given-names>P.</given-names></name></person-group>
<article-title>Preoperative oral supplementation with long-chain Omega-3 fatty acids beneficially alters phospholipid fatty acid patterns in liver, gut mucosa, and tumor tissue</article-title>
<source>J. Parenter. Enter. Nutr.</source>
<year>2005</year>
<volume>29</volume>
<fpage>236</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1177/0148607105029004236</pub-id>
</element-citation></ref><ref id="B12-nutrients-06-04043"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Senkal</surname><given-names>M.</given-names></name><name><surname>Geier</surname><given-names>B.</given-names></name><name><surname>Hannemann</surname><given-names>M.</given-names></name><name><surname>Deska</surname><given-names>T.</given-names></name><name><surname>Linseisen</surname><given-names>J.</given-names></name><name><surname>Wolfram</surname><given-names>G.</given-names></name><name><surname>Adolph</surname><given-names>M.</given-names></name></person-group>
<article-title>Supplementation of omega-3 fatty acids in parenteral nutrition beneficially alters phospholipid fatty acid pattern</article-title>
<source>J. Parenter. Enter. Nutr.</source>
<year>2007</year>
<volume>31</volume>
<fpage>12</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1177/014860710703100112</pub-id>
</element-citation></ref><ref id="B13-nutrients-06-04043"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calder</surname><given-names>P.C.</given-names></name></person-group>
<article-title>Mechanisms of action of (<italic>n</italic>-3) fatty acids</article-title>
<source>J. Nutr.</source>
<year>2012</year>
<volume>142</volume>
<fpage>592S</fpage>
<lpage>599S</lpage>
<pub-id pub-id-type="doi">10.3945/jn.111.155259</pub-id>
<pub-id pub-id-type="pmid">22279140</pub-id></element-citation></ref><ref id="B14-nutrients-06-04043"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stubbs</surname><given-names>C.D.</given-names></name><name><surname>Smith</surname><given-names>A.D.</given-names></name></person-group>
<article-title>The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function</article-title>
<source>Biochim. Biophys. Acta</source>
<year>1984</year>
<volume>779</volume>
<fpage>89</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/0304-4157(84)90005-4</pub-id>
<pub-id pub-id-type="pmid">6229284</pub-id></element-citation></ref><ref id="B15-nutrients-06-04043"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calder</surname><given-names>P.C.</given-names></name></person-group>
<article-title>The relationship between the fatty acid composition of immune cells and their function</article-title>
<source>Prostaglandins Leukot. Essent. Fatty Acids</source>
<year>2008</year>
<volume>79</volume>
<fpage>101</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1016/j.plefa.2008.09.016</pub-id>
<pub-id pub-id-type="pmid">18951005</pub-id></element-citation></ref><ref id="B16-nutrients-06-04043"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terano</surname><given-names>T.</given-names></name><name><surname>Salmon</surname><given-names>J.A.</given-names></name><name><surname>Moncada</surname><given-names>S.</given-names></name></person-group>
<article-title>Biosynthesis and biological activity of leukotriene B5</article-title>
<source>Prostaglandins</source>
<year>1984</year>
<volume>27</volume>
<fpage>217</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1016/0090-6980(84)90075-3</pub-id>
<pub-id pub-id-type="pmid">6326200</pub-id></element-citation></ref><ref id="B17-nutrients-06-04043"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z.M.</given-names></name><name><surname>Wilmore</surname><given-names>D.W.</given-names></name><name><surname>Wang</surname><given-names>X.R.</given-names></name><name><surname>Wei</surname><given-names>J.M.</given-names></name><name><surname>Zhang</surname><given-names>Z.T.</given-names></name><name><surname>Gu</surname><given-names>Z.Y.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Han</surname><given-names>S.M.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>K.</given-names></name></person-group>
<article-title>Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery</article-title>
<source>Br. J. Surg.</source>
<year>2010</year>
<volume>97</volume>
<fpage>804</fpage>
<lpage>809</lpage>
<pub-id pub-id-type="doi">10.1002/bjs.6999</pub-id>
<pub-id pub-id-type="pmid">20473991</pub-id></element-citation></ref><ref id="B18-nutrients-06-04043"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Senkal</surname><given-names>M.</given-names></name><name><surname>Mumme</surname><given-names>A.</given-names></name><name><surname>Eickhoff</surname><given-names>U.</given-names></name><name><surname>Geier</surname><given-names>B.</given-names></name><name><surname>Spath</surname><given-names>G.</given-names></name><name><surname>Wulfert</surname><given-names>D.</given-names></name><name><surname>Joosten</surname><given-names>U.</given-names></name><name><surname>Frei</surname><given-names>A.</given-names></name><name><surname>Kemen</surname><given-names>M.</given-names></name></person-group>
<article-title>Early postoperative enteral immunonutrition: Clinical outcome and cost-comparison analysis in surgical patients</article-title>
<source>Crit. Care Med.</source>
<year>1997</year>
<volume>25</volume>
<fpage>1489</fpage>
<lpage>1496</lpage>
<pub-id pub-id-type="doi">10.1097/00003246-199709000-00015</pub-id>
<pub-id pub-id-type="pmid">9295822</pub-id></element-citation></ref><ref id="B19-nutrients-06-04043"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsekos</surname><given-names>E.</given-names></name><name><surname>Reuter</surname><given-names>C.</given-names></name><name><surname>Stehle</surname><given-names>P.</given-names></name><name><surname>Boeden</surname><given-names>G.</given-names></name></person-group>
<article-title>Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery</article-title>
<source>Clin. Nutr.</source>
<year>2004</year>
<volume>23</volume>
<fpage>325</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">15158295</pub-id></element-citation></ref><ref id="B20-nutrients-06-04043"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiss</surname><given-names>G.</given-names></name><name><surname>Meyer</surname><given-names>F.</given-names></name><name><surname>Matthies</surname><given-names>B.</given-names></name><name><surname>Pross</surname><given-names>M.</given-names></name><name><surname>Koenig</surname><given-names>W.</given-names></name><name><surname>Lippert</surname><given-names>H.</given-names></name></person-group>
<article-title>Immunomodulation by perioperative administration of <italic>n</italic>-3 fatty acids</article-title>
<source>Br. J. Nutr.</source>
<year>2002</year>
<volume>87</volume>
<issue>Suppl. 1</issue>
<fpage>S89</fpage>
<lpage>S94</lpage>
<pub-id pub-id-type="doi">10.1079/BJN2001461</pub-id>
<pub-id pub-id-type="pmid">11895158</pub-id></element-citation></ref><ref id="B21-nutrients-06-04043"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Furst</surname><given-names>P.</given-names></name><name><surname>Kuhn</surname><given-names>K.S.</given-names></name></person-group>
<article-title>Fish oil emulsions: What benefits can they bring?</article-title>
<source>Clin. Nutr.</source>
<year>2000</year>
<volume>19</volume>
<fpage>7</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">10700528</pub-id></element-citation></ref><ref id="B22-nutrients-06-04043"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grimm</surname><given-names>H.</given-names></name><name><surname>Mayer</surname><given-names>K.</given-names></name><name><surname>Mayser</surname><given-names>P.</given-names></name><name><surname>Eigenbrodt</surname><given-names>E.</given-names></name></person-group>
<article-title>Regulatory potential of <italic>n</italic>-3 fatty acids in immunological and inflammatory processes</article-title>
<source>Br. J. Nutr.</source>
<year>2002</year>
<volume>87</volume>
<issue>Suppl. 1</issue>
<fpage>S59</fpage>
<lpage>S67</lpage>
<pub-id pub-id-type="doi">10.1079/BJN2001457</pub-id>
<pub-id pub-id-type="pmid">11895155</pub-id></element-citation></ref><ref id="B23-nutrients-06-04043"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mayer</surname><given-names>K.</given-names></name><name><surname>Grimm</surname><given-names>H.</given-names></name><name><surname>Grimminger</surname><given-names>F.</given-names></name><name><surname>Seeger</surname><given-names>W.</given-names></name></person-group>
<article-title>Parenteral nutrition with <italic>n</italic>-3 lipids in sepsis</article-title>
<source>Br. J. Nutr.</source>
<year>2002</year>
<volume>87</volume>
<issue>Suppl. 1</issue>
<fpage>S69</fpage>
<lpage>S75</lpage>
<pub-id pub-id-type="doi">10.1079/BJN2001458</pub-id>
<pub-id pub-id-type="pmid">11895156</pub-id></element-citation></ref><ref id="B24-nutrients-06-04043"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koller</surname><given-names>M.</given-names></name><name><surname>Senkal</surname><given-names>M.</given-names></name><name><surname>Kemen</surname><given-names>M.</given-names></name><name><surname>Konig</surname><given-names>W.</given-names></name><name><surname>Zumtobel</surname><given-names>V.</given-names></name><name><surname>Muhr</surname><given-names>G.</given-names></name></person-group>
<article-title>Impact of omega-3 fatty acid enriched TPN on leukotriene synthesis by leukocytes after major surgery</article-title>
<source>Clin. Nutr.</source>
<year>2003</year>
<volume>22</volume>
<fpage>59</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1054/clnu.2002.0592</pub-id>
<pub-id pub-id-type="pmid">12553951</pub-id></element-citation></ref><ref id="B25-nutrients-06-04043"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morlion</surname><given-names>B.J.</given-names></name><name><surname>Torwesten</surname><given-names>E.</given-names></name><name><surname>Lessire</surname><given-names>H.</given-names></name><name><surname>Sturm</surname><given-names>G.</given-names></name><name><surname>Peskar</surname><given-names>B.M.</given-names></name><name><surname>Furst</surname><given-names>P.</given-names></name><name><surname>Puchstein</surname><given-names>C.</given-names></name></person-group>
<article-title>The effect of parenteral fish oil on leukocyte membrane fatty acid composition and leukotriene-synthesizing capacity in patients with postoperative trauma</article-title>
<source>Metabolism</source>
<year>1996</year>
<volume>45</volume>
<fpage>1208</fpage>
<lpage>1213</lpage>
<pub-id pub-id-type="doi">10.1016/S0026-0495(96)90237-1</pub-id>
<pub-id pub-id-type="pmid">8843174</pub-id></element-citation></ref><ref id="B26-nutrients-06-04043"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wachtler</surname><given-names>P.</given-names></name><name><surname>Axel</surname><given-names>H.R.</given-names></name><name><surname>Konig</surname><given-names>W.</given-names></name><name><surname>Bauer</surname><given-names>K.H.</given-names></name><name><surname>Kemen</surname><given-names>M.</given-names></name><name><surname>Koller</surname><given-names>M.</given-names></name></person-group>
<article-title>Influence of a pre-operative enteral supplement on functional activities of peripheral leukocytes from patients with major surgery</article-title>
<source>Clin. Nutr.</source>
<year>1995</year>
<volume>14</volume>
<fpage>275</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1016/S0261-5614(95)80064-6</pub-id>
<pub-id pub-id-type="pmid">16843943</pub-id></element-citation></ref><ref id="B27-nutrients-06-04043"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schauder</surname><given-names>P.</given-names></name><name><surname>Rohn</surname><given-names>U.</given-names></name><name><surname>Schafer</surname><given-names>G.</given-names></name><name><surname>Korff</surname><given-names>G.</given-names></name><name><surname>Schenk</surname><given-names>H.D.</given-names></name></person-group>
<article-title>Impact of fish oil enriched total parenteral nutrition on DNA synthesis, cytokine release and receptor expression by lymphocytes in the postoperative period</article-title>
<source>Br. J. Nutr.</source>
<year>2002</year>
<volume>87</volume>
<issue>Suppl. 1</issue>
<fpage>S103</fpage>
<lpage>S110</lpage>
<pub-id pub-id-type="doi">10.1079/BJN2001463</pub-id>
<pub-id pub-id-type="pmid">11895146</pub-id></element-citation></ref><ref id="B28-nutrients-06-04043"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>L.S.</given-names></name><name><surname>Thorlacius-Ussing</surname><given-names>O.</given-names></name><name><surname>Schmidt</surname><given-names>E.B.</given-names></name><name><surname>Rasmussen</surname><given-names>H.H.</given-names></name><name><surname>Lundbye-Christensen</surname><given-names>S.</given-names></name><name><surname>Calder</surname><given-names>P.C.</given-names></name><name><surname>Lindorff-Larsen</surname><given-names>K.</given-names></name></person-group>
<article-title>Randomized clinical trial of perioperative omega-3 fatty acid supplements in elective colorectal cancer surgery</article-title>
<source>Br. J. Surg.</source>
<year>2014</year>
<volume>101</volume>
<fpage>33</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1002/bjs.9361</pub-id>
<pub-id pub-id-type="pmid">24281905</pub-id></element-citation></ref><ref id="B29-nutrients-06-04043"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moher</surname><given-names>D.</given-names></name><name><surname>Hopewell</surname><given-names>S.</given-names></name><name><surname>Schulz</surname><given-names>K.F.</given-names></name><name><surname>Montori</surname><given-names>V.</given-names></name><name><surname>Gotzsche</surname><given-names>P.C.</given-names></name><name><surname>Devereaux</surname><given-names>P.J.</given-names></name><name><surname>Elbourne</surname><given-names>D.</given-names></name><name><surname>Egger</surname><given-names>M.</given-names></name><name><surname>Altman</surname><given-names>D.G.</given-names></name></person-group>
<article-title>CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials</article-title>
<source>J. Clin. Epidemiol.</source>
<year>2010</year>
<volume>63</volume>
<fpage>e1</fpage>
<lpage>e37</lpage>
<pub-id pub-id-type="doi">10.1016/j.jclinepi.2010.03.004</pub-id>
<pub-id pub-id-type="pmid">20346624</pub-id></element-citation></ref><ref id="B30-nutrients-06-04043"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wolters</surname><given-names>U.</given-names></name><name><surname>Wolf</surname><given-names>T.</given-names></name><name><surname>Stutzer</surname><given-names>H.</given-names></name><name><surname>Schroder</surname><given-names>T.</given-names></name></person-group>
<article-title>ASA classification and perioperative variables as predictors of postoperative outcome</article-title>
<source>Br. J. Anaesth.</source>
<year>1996</year>
<volume>77</volume>
<fpage>217</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="doi">10.1093/bja/77.2.217</pub-id>
<pub-id pub-id-type="pmid">8881629</pub-id></element-citation></ref><ref id="B31-nutrients-06-04043"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kondrup</surname><given-names>J.</given-names></name><name><surname>Rasmussen</surname><given-names>H.H.</given-names></name><name><surname>Hamberg</surname><given-names>O.</given-names></name><name><surname>Stanga</surname><given-names>Z.</given-names></name></person-group>
<article-title>Nutritional risk screening (NRS 2002): A new method based on an analysis of controlled clinical trials</article-title>
<source>Clin. Nutr.</source>
<year>2003</year>
<volume>22</volume>
<fpage>321</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="doi">10.1016/S0261-5614(02)00214-5</pub-id>
<pub-id pub-id-type="pmid">12765673</pub-id></element-citation></ref><ref id="B32-nutrients-06-04043"><label>32.</label><element-citation publication-type="gov">
<article-title>A Service of the U.S. National Institutes of Health</article-title>
<comment>Available online:<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00488904?term=NCT00488904&#x00026;rank=1">http://clinicaltrials.gov/ct2/show/NCT00488904?term=NCT00488904&#x00026;rank=1</ext-link></comment>
<date-in-citation>(accessed on 4 September 2010)</date-in-citation>
</element-citation></ref><ref id="B33-nutrients-06-04043"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>M.S.</given-names></name><name><surname>Gammelmark</surname><given-names>A.</given-names></name><name><surname>Madsen</surname><given-names>T.</given-names></name><name><surname>Obel</surname><given-names>T.</given-names></name><name><surname>Aardestrup</surname><given-names>I.</given-names></name><name><surname>Schmidt</surname><given-names>E.B.</given-names></name></person-group>
<article-title>The effect of low-dose marine <italic>n</italic>-3 fatty acids on the biosynthesis of pro-inflammatory 5-lipoxygenase pathway metabolites in overweight subjects: A randomized controlled trial</article-title>
<source>Prostaglandins Leukot. Essent. Fatty Acids</source>
<year>2012</year>
<volume>87</volume>
<fpage>43</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1016/j.plefa.2012.05.009</pub-id>
<pub-id pub-id-type="pmid">22748976</pub-id></element-citation></ref><ref id="B34-nutrients-06-04043"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Powell</surname><given-names>W.S.</given-names></name><name><surname>Gravel</surname><given-names>S.</given-names></name><name><surname>Gravelle</surname><given-names>F.</given-names></name></person-group>
<article-title>Formation of a 5-oxo metabolite of 5,8,11,14,17-eicosapentaenoic acid and its effects on human neutrophils and eosinophils</article-title>
<source>J. Lipid Res.</source>
<year>1995</year>
<volume>36</volume>
<fpage>2590</fpage>
<lpage>2598</lpage>
<pub-id pub-id-type="pmid">8847485</pub-id></element-citation></ref><ref id="B35-nutrients-06-04043"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>L.S.</given-names></name><name><surname>Rasmussen</surname><given-names>H.H.</given-names></name><name><surname>Aardestrup</surname><given-names>I.V.</given-names></name><name><surname>Thorlacius-Ussing</surname><given-names>O.</given-names></name><name><surname>Lindorff-Larsen</surname><given-names>K.</given-names></name><name><surname>Schmidt</surname><given-names>E.B.</given-names></name><name><surname>Calder</surname><given-names>P.C.</given-names></name></person-group>
<article-title>Rapid Incorporation of omega-3 Fatty Acids Into Colonic Tissue After Oral Supplementation in Patients With Colorectal Cancer: A Randomized, Placebo-Controlled Intervention Trial</article-title>
<source>J. Parenter. Enter. Nutr.</source>
<year>2013</year>
<volume>38</volume>
<fpage>617</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="doi">10.1177/0148607113491782</pub-id>
</element-citation></ref><ref id="B36-nutrients-06-04043"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grimm</surname><given-names>H.</given-names></name><name><surname>Mertes</surname><given-names>N.</given-names></name><name><surname>Goeters</surname><given-names>C.</given-names></name><name><surname>Schlotzer</surname><given-names>E.</given-names></name><name><surname>Mayer</surname><given-names>K.</given-names></name><name><surname>Grimminger</surname><given-names>F.</given-names></name><name><surname>Furst</surname><given-names>P.</given-names></name></person-group>
<article-title>Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients</article-title>
<source>Eur. J. Nutr.</source>
<year>2006</year>
<volume>45</volume>
<fpage>55</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">16041475</pub-id></element-citation></ref><ref id="B37-nutrients-06-04043"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>J.C.</given-names></name><name><surname>Kang</surname><given-names>W.M.</given-names></name><name><surname>Ma</surname><given-names>Z.Q.</given-names></name></person-group>
<article-title>Superiority of a fish oil-enriched emulsion to medium-chain triacylglycerols/long-chain triacylglycerols in gastrointestinal surgery patients: A randomized clinical trial</article-title>
<source>Nutrition</source>
<year>2012</year>
<volume>28</volume>
<fpage>623</fpage>
<lpage>629</lpage>
<pub-id pub-id-type="doi">10.1016/j.nut.2011.08.004</pub-id>
<pub-id pub-id-type="pmid">22113064</pub-id></element-citation></ref><ref id="B38-nutrients-06-04043"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>T.</given-names></name><name><surname>Fujii</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>R.</given-names></name><name><surname>Igarashi</surname><given-names>J.</given-names></name><name><surname>Ohtsuka</surname><given-names>Y.</given-names></name><name><surname>Nagata</surname><given-names>S.</given-names></name><name><surname>Yamashiro</surname><given-names>Y.</given-names></name></person-group>
<article-title>Effects of highly purified eicosapentaenoic acid on erythrocyte fatty acid composition and leukocyte and colonic mucosa leukotriene B4 production in children with ulcerative colitis</article-title>
<source>J. Pediatr. Gastroenterol. Nutr.</source>
<year>2003</year>
<volume>37</volume>
<fpage>581</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="doi">10.1097/00005176-200311000-00015</pub-id>
<pub-id pub-id-type="pmid">14581801</pub-id></element-citation></ref><ref id="B39-nutrients-06-04043"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carpentier</surname><given-names>Y.A.</given-names></name><name><surname>Simoens</surname><given-names>C.</given-names></name><name><surname>Siderova</surname><given-names>V.</given-names></name><name><surname>Vanweyenberg</surname><given-names>V.</given-names></name><name><surname>Eggerickx</surname><given-names>D.</given-names></name><name><surname>Deckelbaum</surname><given-names>R.J.</given-names></name></person-group>
<article-title>Recent developments in lipid emulsions: Relevance to intensive care</article-title>
<source>Nutrition</source>
<year>1997</year>
<volume>13</volume>
<fpage>73S</fpage>
<lpage>78S</lpage>
<pub-id pub-id-type="doi">10.1016/S0899-9007(97)83047-X</pub-id>
<pub-id pub-id-type="pmid">9290113</pub-id></element-citation></ref><ref id="B40-nutrients-06-04043"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barros</surname><given-names>K.V.</given-names></name><name><surname>Carvalho</surname><given-names>P.O.</given-names></name><name><surname>Cassulino</surname><given-names>A.P.</given-names></name><name><surname>Andrade</surname><given-names>I.</given-names></name><name><surname>West</surname><given-names>A.L.</given-names></name><name><surname>Miles</surname><given-names>E.A.</given-names></name><name><surname>Calder</surname><given-names>P.C.</given-names></name><name><surname>Silveira</surname><given-names>V.L.</given-names></name></person-group>
<article-title>Fatty acids in plasma, white and red blood cells, and tissues after oral or intravenous administration of fish oil in rats</article-title>
<source>Clin. Nutr.</source>
<year>2013</year>
<volume>32</volume>
<fpage>993</fpage>
<lpage>998</lpage>
<pub-id pub-id-type="doi">10.1016/j.clnu.2013.02.010</pub-id>
<pub-id pub-id-type="pmid">23541913</pub-id></element-citation></ref></ref-list></back></article>